Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

華潤醫藥集團有限公司
China Resources Pharmaceutical Group Limited
(Incorporated in Hong Kong with limited liability)
(Stock Code: 3320)

ANNOUNCEMENT

RESULTS ESTIMATE OF DONG-E-E-JIAO FOR THE YEAR ENDED 31 DECEMBER 2021

On 27 January 2022, Dong-E-E-Jiao released its results estimate for the year ended 31 December 2021.

Dong-E-E-Jiao Company Limited (東阿阿膠股份有限公司) ("**Dong-E-E-Jiao**") is a company incorporated in the People's Republic of China. The shares of Dong-E-E-Jiao are listed on the Shenzhen Stock Exchange. As of the date of this announcement, Dong-E-E-Jiao is directly held as to 8.86% of its equity interests by China Resources Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") and approximately 23.14% is held by the Company through its non-wholly owned subsidiary, China Resources Dong-E-E-Jiao Company Limited (華潤東阿阿膠有限公司). The Group effectively controls approximately 21.96% of Dong-E-E-Jiao. Dong-E-E-Jiao is accounted for as a subsidiary of the Company.

On 27 January 2022, Dong-E-E-Jiao released its results estimate for the year ended 31 December 2021, in which, it announced that the net profit attributable to the shareholders of Dong-E-E-Jiao for the year ended 31 December 2021 is estimated to range from approximately RMB427.50 million to RMB474.75 million (as compared to the same period last year of net profit of approximately RMB43.29 million), net profit excluding non-recurring gain or loss is estimated to range from approximately RMB345.07 million to RMB383.21 million (as compared to the same period last year of net loss of approximately RMB39.46 million), basic earnings per share is estimated to range from approximately RMB0.66 per share to approximately RMB0.74 per share (as compared to the same period last year of profit per share of approximately RMB0.07 per share) (the "**Dong-E-E-Jiao Results Estimate**").

The main reasons for the change in results are set forth as follows:

1. In line with its persistent consumer-centric approach and focus on growing and retaining customers, Dong-E-E-Jiao accelerated product innovation and enhanced the commercialisation of scientific research, resulting in ongoing release of brand productivity and the achievement of sound and stable growth.

2. In the future, in active response the nation's call for the development of Chinese medicine through innovation as well as heritage, Dong-E-E-Jiao will step up with its digital transformation and business model innovation based on customers' requirements with the aim of becoming the "major health enterprise in the Chinese nutritious health sector most trusted by its consumers"; and with intensive effort in the "reshaping of values, business, organisation and ethos", it will fortify its leading market position of its core products and increase the product variety of its existing brands to provide solutions that meet the needs of the market and the customers, while enhancing its organisational capability for digital transformation to advance the qualitative development of Dong-E-E-Jiao.

The Dong-E-E-Jiao Results Estimate was prepared in accordance with the PRC Generally Accepted Accounting Principles and has not been audited or reviewed. For details of the financial data, those to be disclosed in the annual report for the year ended 31 December 2021 to be issued by Dong-E-E-Jiao shall prevail.

The financial information in this announcement is limited to Dong-E-E-Jiao only and does not represent or provide a complete view of the operational of financial status of the Group.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
China Resources Pharmaceutical Group Limited
Han Yuewei
Chairman

Shenzhen, 28 January 2022

As at the date of this announcement, the Board comprises Mr. Han Yuewei as chairman and non-executive Director, Mr. Bai Xiaosong, Mdm. Weng Jingwen and Mr. Tao Ran as executive Directors, Mr. Lin Guolong, Mr. Tan Ying, Mr. Hou Bo and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.